Atomic clarity: how structural biology is shaping blood-stage malaria vaccines

Abstract

Developing an effective malaria vaccine is challenging because Plasmodium parasites use complex strategies to invade host cells. The blood stage, where parasites replicate inside red blood cells, causes disease symptoms and relies on large multiprotein surface complexes that are difficult to target. Understanding their structure is essential for rational vaccine design. Cryogenic electron microscopy (cryoEM) enables atomic-level analysis of dynamic and membrane-associated complexes without crystallization, revealing key processes such as protein trafficking, nutrient uptake, and host cell remodeling. Recent advances in artificial intelligence and deep learning have improved cryoEM data analysis and structural modeling. Together with genomic data, this integrated approach is accelerating progress toward broadly protective malaria vaccines.

Beyond single antigens: rethinking blood-stage malaria vaccines

The blood stage of malaria is the most clinically damaging phase of infection, during which Plasmodium parasites invade red blood cells (RBCs), manifesting as symptoms fever, chills, headache, fatigue, etc. and often progressing to severe complications such as cerebral malaria and life-threatening anemia; vaccines targeting this stage aim to curb both disease pathology and parasite proliferation. To date, 16 blood-stage antigens have entered or completed clinical trials, with key candidates including MSP1, MSP3, AMA1, EBA175, PfRH5 and PvRBP2b, each playing a critical role in the parasite’s red blood cell (RBC) invasion cascade.¹ These vaccine candidates have largely focused on single-antigen targets; however, this approach has shown limited efficacy due to the parasite’s complex and redundant invasion mechanisms. Notably, many of these antigens function as components of multiprotein complexes that mediate receptor binding and membrane penetration. Elucidating these complexes at atomic-level resolution is indispensable for rational vaccine design.²

The cryogenic electron microscopy revolution in malaria structural vaccinology

Traditional structural biology tools such as X-ray crystallography, which excels in high resolution but is hampered by the need for crystallization, is particularly challenging for flexible or membrane-associated Plasmodium proteins. NMR spectroscopy, ideal for small, soluble proteins but less suited for large complexes, has now been joined and often surpassed by cryogenic electron microscopy (cryoEM). CryoEM, following its impact with the 2017 Nobel Prize in Chemistry awarded to Dubochet, Frank and Henderson, has transformed structural biology by enabling imaging of large, dynamic protein complexes in near-native states without crystallization. This technique has revolutionized malaria research, revealing the structures of pivotal complexes: the P. falciparum 20S proteasome (~3.6 Å resolution) complexed with a parasite-specific inhibitor³; the PTEX core complex, key to protein export across the parasitophorous vacuole membrane, resolved in a 6:7:7 stoichiometry⁴; the RhopH complex, essential for nutrient uptake, isolated directly from parasite lysates and shown to comprise CLAG3, RhopH2 and RhopH3 in a 1:1:1 ratio⁵ ; and PfMSP1 resolved at ~3.1 Å, mapping its conformational flexibility and interactions with erythrocyte receptors such as glycophorin A and band 3.⁶ Importantly, high-resolution structural insights have enabled precise epitope mapping, antigen stabilization, and immune focusing. By defining antigen–antibody interfaces and conformational states, these advances have directly informed rational immunogen engineering for improved protective efficacy. These structural insights have accelerated structure-guided immunogen design, exemplified by the synthetic immunogen RH5-34EM, which mimics a neutralizing PfRH5 epitope and demonstrates correct folding and high-affinity monoclonal antibody binding. These studies underscore the power of cryoEM in revealing functional epitopes with atomic precision. Further progress includes a thermally stabilized PfRH5 variant, engineered through computational techniques (e.g. phylogenetics and Rosetta modeling) to enhance thermostability by ~10–15 °C while maintaining immunogenicity and enabling Escherichia coli expression, an advance poised to support low-cost, field-ready vaccines.⁷

Toward multistage structural vaccinology in malaria

Structural elucidation of the PfRH5−CyRPA−RIPR (PfRCR) invasion complex has a deepened understanding of RBC invasion mechanics and spurred formulation of combination immunogens such as RH5.1 with RIPR’s C-terminal EGF-like fusion (R78C). These immunogens show enhanced in vitro growth inhibition relative to RH5 alone and are advancing toward early clinical evaluation.⁸ In parallel, transmission-blocking vaccines (TBVs) represent a complementary strategy aimed not only at preventing disease in the vaccinated individual but also at interrupting parasite development within the mosquito vector. A recent cryoEM structure of the Pfs230–Pfs48/45 fertilization complex directly purified from parasites has provided unprecedented structural insight into sexualstage biology⁹. This study resulted in the discovery of previously unrecognized binding regions essential for parasite fertilization. An mRNA vaccine was designed targeting these sites, which blocked transmission in mosquitoes by up to 99.7% in preclinical models.⁹ This breakthrough exemplifies the potential of TBVs, complementing blood-stage and liver-stage strategies, to create a multistage malaria vaccine arsenal.

However, despite promising preclinical efficacy, several challenges remain in developing an efficacious blood-stage vaccine. Growth inhibition assays do not always predict in-vivo protection, and RH5-based vaccines, while strain-transcendent in theory, may still face antigenic variation pressures or immune escape in diverse endemic settings. Moreover, the structural stability and manufacturability of multicomponent immunogens require careful optimization to ensure scalability and consistent immunogenicity.

The artificial intelligence revolution in cryoEM structural biology

CryoEM has transformed structural biology by enabling near-atomic visualization of macromolecular complexes. However, important challenges remain: datasets are inherently noisy, biological samples are frequently heterogeneous and dynamic, and high-resolution reconstruction demands substantial computational resources. To address these limitations, artificial intelligence (AI) and deep learning (DL) are increasingly integrated into cryoEM workflows, enhancing both data interpretation and structural modeling.

These advances are particularly relevant for studying Plasmodium proteins, which undergo extensive post-translational modifications (PTMs). Modeling post-translational modifications remains challenging in structural analyses. In Plasmodium, glycosylation is highly reduced and atypical, with minimal N-linked glycosylation and GPI anchors as the predominant carbohydrate modification in blood-stage parasites. These sparse and heterogeneous glycans are often unresolved in cryoEM maps and are not well captured by current AI-based prediction tools. Consequently, incomplete representation of parasite-specific glycosylation may affect antigen surface topology and epitope accessibility in structure-guided vaccine design.

Recent advances illustrate this shift. Graph neural network-based approaches now enable automated model building by refining amino acid placement in cryoEM maps at resolutions better than ~3.5 Å, substantially reducing manual intervention.¹⁰ Similarly, DeepTracer-LowResEnhance combines DL-based map refinement with AlphaFold to improve model construction from low-resolution maps (2.5–8.4 Å), reporting a 95.5% increase in modeled residues for challenging datasets.¹¹ The emergence of AlphaFold 3, capable of predicting protein complexes, including those involving DNA, RNA, ligands and post-translational modifications, further complements cryoEM by bridging gaps where experimental resolution is limited. Beyond atomic model building, DL is reshaping tomographic reconstruction. IsoNet, a convolutional neural network-based framework, compensates for the missing-wedge effect in electron tomography, enabling isotropic reconstruction from low-resolution tomograms (~10 Å pixel size) through iterative learning from original structural features.¹² At the workflow level, CryoAI accelerates 3D volume reconstruction via amortized pose inference, while CryoRL applies reinforcement learning to optimize cryoEM data acquisition across heterogeneous grids. Together, these innovations reduce computational burden, improve reconstruction fidelity and enhance overall data quality.¹³

Crucially, these AI-enabled structural advances extend beyond methodology and directly inform vaccine development. By integrating genomic surveillance of antigenic diversity with high-resolution structural mapping and AI-enhanced modeling, a genomics-to-vaccine pipeline is emerging. This framework supports rapid identification of conserved epitopes, optimization of antigen stability and iterative refinement of synthetic immunogens and mRNA-based candidates. In this way, structural biology and AI converge to enable adaptive vaccine design capable of responding to evolving Plasmodium strains, accelerating preclinical validation and translational readiness.

Conclusion

In the fight against malaria, the convergence of cryoEM, genomics and AI is transforming how we understand and target the parasite. These integrated approaches are unraveling the architecture of key antigens and invasion complexes while enabling precision immunogen design to address antigenic variability. With cryoEM delivering near-atomic resolution of challenging targets and AI accelerating structural interpretation and predictive modeling, malaria vaccine development is entering a new era of rational, adaptable engineering. Yet structural precision does not automatically translate into clinical efficacy. Reliable correlates of protection remain incompletely defined, and in-vitro readouts do not always predict field performance. Significant translational bottlenecks persist. Multicomponent and structurally optimized immunogens must be engineered for stability, manufacturability, thermostability and cost-effectiveness to ensure scalability in endemic regions. Transmission-blocking vaccines face additional challenges, including the need for durable, high-titer antibody responses and clear demonstration of community-level impact.

Regulatory pathways for next-generation platforms, such as mRNA-based and AI-guided vaccine designs, will require standardized immunological endpoints, robust validation frameworks, and coordinated global evaluation strategies. Moving forward, priority areas include integrating structural insights with longitudinal immuno-epidemiological data to define protective signatures; designing multistage immunogens that balance immune breadth with focused responses; leveraging AI for predictive antigen optimization and variant surveillance; and strengthening translational pipelines that bridge structural discovery with clinical development in endemic populations.

By integrating advances in structural biology and genomics with rigorous field validation and immuno-epidemiological insights, and aligning these with translational and regulatory readiness, this multidisciplinary synergy holds the potential to outpace Plasmodium’s evasive biology and deliver a truly effective, broad-spectrum malaria vaccine, marking a transformative milestone in global health and disease elimination.

Data availability

There are no new data associated with this article.